Division 3, Department of Hepatology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Division 2, Department of Hepatology, The Fourth People's Hospital of Qinghai Province, Xining, 810000, China.
Can J Gastroenterol Hepatol. 2021 Sep 27;2021:4073503. doi: 10.1155/2021/4073503. eCollection 2021.
Alcohol-related liver disease is an increasing public health burden in China, but there is a lack of models to predict its prognosis. This study established a nomogram for predicting the survival of Chinese patients with alcohol-related liver disease (ALD).
Hospitalized alcohol-related liver disease patients were retrospectively enrolled from 2015 to 2018 and followed up for 24 months to evaluate survival profiles. A total of 379 patients were divided into a training cohort ( = 265) and validation cohort ( = 114). Cox proportional hazard survival analysis identified survival factors of the patients in the training cohort. A nomogram was built and internally validated.
The 3-month, 6-month, 12-month, and 24-month survival rates for the training cohort were 82.6%, 81.1%, 74.3%, and 64.5%, respectively. The Cox analysis showed relapse (=0.001), cirrhosis (=0.044), liver cancer ( < 0.001), and a model for end-stage liver diseases score of ≥21 (=0.041) as independent prognostic factors. A nomogram was built, which predicted the survival of patients in the training cohort with a concordance index of 0.749 and in the internal validation cohort with a concordance index of 0.756.
The long-term survival of Chinese alcohol-related liver disease patients was poor with a 24-month survival rate of 64.5%. Relapse, cirrhosis, liver cancer, and a model for end-stage liver disease score of ≥21 were independent risk factors for those patients. A nomogram was developed and internally validated for predicting the probability of their survival at different time points.
酒精性肝病在中国是一个日益严重的公共卫生负担,但缺乏预测其预后的模型。本研究建立了一个预测中国酒精性肝病(ALD)患者生存的列线图。
回顾性纳入 2015 年至 2018 年住院的酒精性肝病患者,并随访 24 个月以评估生存情况。共纳入 379 例患者,分为训练队列(n=265)和验证队列(n=114)。Cox 比例风险生存分析确定了训练队列患者的生存因素。建立了一个列线图并进行内部验证。
训练队列的 3 个月、6 个月、12 个月和 24 个月的生存率分别为 82.6%、81.1%、74.3%和 64.5%。Cox 分析显示,复发(=0.001)、肝硬化(=0.044)、肝癌(<0.001)和终末期肝病模型评分≥21(=0.041)是独立的预后因素。建立了一个列线图,该图预测了训练队列患者的生存情况,其一致性指数为 0.749,内部验证队列的一致性指数为 0.756。
中国酒精性肝病患者的长期生存率较差,24 个月生存率为 64.5%。复发、肝硬化、肝癌和终末期肝病模型评分≥21 是这些患者的独立危险因素。开发了一个列线图并进行了内部验证,以预测不同时间点的生存概率。